Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Sunday, December 22, 2024 · 771,091,069 Articles · 3+ Million Readers

Advancing Stem Cell Research: Creative Biolabs Unveils Innovative Solutions

Creative Biolabs

CreativeBiolabs

With upgraded technologies and one-stop scientific solutions, Creative Biolabs continues to promote discoveries in stem cell therapy research.

SHIRLEY, NY, UNITED STATES, December 19, 2024 /EINPresswire.com/ -- Stem cell therapy, as an important research field in regenerative medicine and the treatment of various diseases, has made significant progress in recent years. Scientists have successfully used induced pluripotent stem cells (iPSCs) for disease modeling, drug screening, and potential cell replacement therapy. However, despite advances in technology, stem cell research still faces many challenges. With a dedicated team of scientists and an array of advanced technologies, Creative Biolabs is committed to pushing the boundaries of stem cell therapy research. They offer custom solutions tailored to meet the specific needs of researchers in this evolving field.

Creative Biolabs provides iPSC reprogramming services to help scientists obtain their desired iPSCs, accelerating research and breakthroughs in regenerative medicine, disease modeling, and drug discovery.

"Recently, fibroblast growth factor 2 (FGF2) has gained much attention due to its promising applications in stem cell therapy research. For example, by regulating the expression of FGF2 or adding FGF2, stem cells can differentiate into specific cell lines. This is significant for regenerative medicine and tissue engineering," said a scientist at this company.

With a dedication to advancing stem cell therapy research, Creative Biolabs recently released a new product, FGF2. Two different versions of FGF2 are provided—FGF2 and FGF2 STAB—that can enhance cell growth and proliferation of human mesenchymal stem cells (MSCs) and normal human dermal fibroblasts (NHDFs).

"We're delighted to introduce FGF2 products to the market," said Creative Biolabs’ product manager. "Their high purity and good design address the critical needs of researchers, enabling them to advance stem cell therapy research."

In addition, Creative Biolabs provides macrophage-related services and products to support stem cell research.. For example, mouse bone marrow-derived macrophages promote the proliferation and differentiation of stem cells by releasing growth factors, cytokines, and other substances; advanced technologies to identify the M1/M2 macrophage phenotype.

"For years, our talented scientists have been at the forefront of the discovery, understanding, and development of stem cell therapies. By integrating experts and advanced technologies, we trust that our services and products can effectively support the discoveries in stem cell therapy. Custom solutions are provided to meet specific research needs," said the director of Creative Biolabs.

Learn more services and products to support your stem cell research, please visit https://www.creative-biolabs.com/stem-cell-therapy/.

About Creative Biolabs
Creative Biolabs supports stem cell therapy research with comprehensive innovative solutions and assay services. Creative Biolabs offers iPSC reprogramming, culture, genome editing, macrophage-related services, and FGF2 products that can be used by scientists working on stem cell, disease therapy, cell therapy, and immunology research around the world.

Candy Swift
Creative Biolabs
+1 631-830-6441
email us here

Powered by EIN Presswire

Distribution channels: Healthcare & Pharmaceuticals Industry, Science, Technology

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Submit your press release